Inclusion Criteria:  Age > or = 18 years Liver transplantation from a deceased donor after brain death (DBD) Model for End-stage Liver Disease Sodium (MELD-Na) score > or = 25 at the time of transplant (not counting MELD exception points) Patient requiring > 0.05 mcg/kg/min of norepinephrine (NE) during LT  Exclusion Criteria:  Living-donor liver transplantation (LDLT) Split liver transplantation (isolated right or left lobe) Donation after cardiac death (DCD) Acute liver failure (ALF) Listed for or receiving simultaneous liver-kidney transplantation (SLKT) Liver re-transplantation (patient who has previously received a liver transplant) Preoperative treatment with angiotensin II receptor blocker or angiotensin converting enzyme inhibitor (within 48 h) Portopulmonary hypertension Left ventricular systolic dysfunction (defined as ejection fraction < 45%) Active bronchospasm at time of LT History of thrombotic or embolic disease, inherited hypercoagulable disorder, or therapeutic anticoagulation Portal vein thrombosis Celiac stenosis End-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or chronic RRT - not including AKI requiring RRT) History of Raynaud's disease Known history of allergy to synthetic human angiotensin II Subject intubated and/or mechanically ventilated prior to entering OR for LT Presence of other condition or abnormality that would compromise the safety of the patient or quality of the data